Mark Breidenbach
Stock Analyst at Oppenheimer
(1.67)
# 3,435
Out of 5,245 analysts
48
Total ratings
30.91%
Success rate
0.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.00 | +250.00% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $17.50 | +71.43% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $9.09 | +945.10% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.39 | +363.82% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $300 | $21.47 | +1,297.30% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $7.92 | +2,930.30% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.06 | +5,128.76% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.80 | +150.00% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $2.10 | +1,423.81% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $4.11 | +264.96% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.6321 | +1,542,377.46% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.00
Upside: +250.00%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $17.50
Upside: +71.43%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $9.09
Upside: +945.10%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.39
Upside: +363.82%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $300
Current: $21.47
Upside: +1,297.30%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $7.92
Upside: +2,930.30%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.06
Upside: +5,128.76%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.80
Upside: +150.00%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $2.10
Upside: +1,423.81%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $4.11
Upside: +264.96%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.6321
Upside: +1,542,377.46%